The Top 5 Biosimilar Articles for the Week of August 3

Here are the top 5 biosimilar articles for the week of August 3, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 3, 2020.

Number 5: The World Health Organization’s (WHO) prequalification of Celltrion Healthcare’s trastuzumab known as Herzuma, opens the door for more affordable access to care for patients with breast and gastric cancers.

Number 4: The uptake of infliximab biosimilars in the United States is slow but tracks closely to the experience in Europe, where after 2 years infliximab biosimilars assumed a large share of the market, according to a new study.

Number 3: Vizient predicts that drug price inflation, partly due to the coronavirus disease 2019 (COVID-19) pandemic, will be 3.29% in 2021 and is banking on biosimilars to help contain the rising cost of medications, it said in a comprehensive review for its member health companies.

Number 2: Amid the confusion of the pandemic, fundamental business strategies are reshaping the biosimilar playing field, according to corporate earnings reports from Alexion, Biogen, Samsung Bioepis and Frensenius Kabi

Number 1: Despite there being concerns over the safety of nonmedical switching between a reference product and a biosimilar, there is a growing body of evidence supporting the safety of switching, according to an executive of Sandoz, which produces biosimilars.

To read all of these articles and more, visit